Efficacy and imaging evaluation of 177Lu-labeled antibody-drug conjugates as a potential theranostic agent for HER2-positive breast cancer

被引：0
|
作者：
Kim, Heejung [1 ]
Shin, Eunbi [1 ]
Lee, JooHyun [1 ]
Yoo, Ran Ji [1 ]
Park, Jang Woo [1 ]
Chung, Hye Kyung [1 ]
Shim, Jae-Hoon [1 ]
机构：
[1] Korea Inst Radiol & Med Sci KIRAMS, Seoul, South Korea
来源：
NUCLEAR MEDICINE AND BIOLOGY | 2021年 / 96-97卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
SP-124
引用
收藏
页码：S104 / S105
页数：2
相关论文
共 50 条
  • [11] Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
    Ferraro, Emanuela
    Drago, Joshua Z.
    Modi, Shanu
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [12] The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates
    Escriva-de-Romani, Santiago
    Saura, Cristina
    CANCER DRUG RESISTANCE, 2023, 6 (01) : 45 - 58
  • [13] Evaluation of 177Lu-Labeled Pertuzumab F(ab′)2 Fragments for HER2-Positive Cancer Targeting: A Comparative In Vitro and In Vivo Study
    Sharma, Rohit
    Mukherjee, Archana
    Kumar, Anuj
    Sarma, Haladhar Dev
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2024, 39 (01) : 64 - 74
  • [14] Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific affibody molecule
    Tolmachev, Vladimir
    Orlova, Anna
    Pehrson, Rikard
    Galli, Joakim
    Baastrup, Barbro
    Andersson, Karl
    Sandstrom, Mattias
    Rosik, Daniel
    Carlsson, Jorgen
    Lundqvist, Hans
    Wennborg, Anders
    Nilsson, Fredrik Y.
    CANCER RESEARCH, 2007, 67 (06) : 2773 - 2782
  • [15] Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model
    Wu, Yitian
    Li, Tuo
    Zhang, Xianzhong
    Jing, Hongli
    Li, Fang
    Huo, Li
    EJNMMI RADIOPHARMACY AND CHEMISTRY, 2024, 9 (01)
  • [16] Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model
    Yitian Wu
    Tuo li
    Xianzhong Zhang
    Hongli Jing
    Fang Li
    Li Huo
    EJNMMI Radiopharmacy and Chemistry, 9
  • [17] Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer
    Burris, Howard A., III
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (06) : 807 - 819
  • [18] Trastuzumab Emtansine: A Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer
    Krop, Ian
    Winer, Eric P.
    CLINICAL CANCER RESEARCH, 2014, 20 (01) : 15 - 20
  • [19] In Vitro Assessment of 177Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer
    Tuncel, Ayca
    Maschauer, Simone
    Prante, Olaf
    Yurt, Fatma
    PHARMACEUTICALS, 2024, 17 (06)
  • [20] Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2
    Abelman, Rachel Occhiogrosso
    Medford, Arielle
    Spring, Laura
    Bardia, Aditya
    CANCER JOURNAL, 2022, 28 (06): : 423 - 428
12345